Pharmaceuticals, Biotechnology and Life Sciences
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
Galapagos NV has started two new Phase 2 studies of filgotinib in small bowel Crohn`s disease and in fistulizing Crohn`s disease, both led by filgotinib collaboration partner Gilead Sciences.
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.